• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Human Monoclonal Antibody
    2 Drugs classified under this drug class


    All the Drug Class Drugs

    Aimovig 70 mg
    Novartis
    RX
    not in the basket chart
    Aimovig 70 mg

    CGRP, Human Monoclonal Antibody. Erenumab 70 mg.
    PRE-FILL. SYR (sol. for S.C. inj.): 1
    PRE- FIL. PEN (sol. for S.C. inj.): 1
    Tmt. is intend. for pts. with at least 4 migraine days per month when initiat. tmt. with erenumab.
    The recomm. dose is 70 mg erenumab every 4 wks. Some pts. may benefit from a dose of 140 mg every 4 wks.
    Each 140 mg dose is given as two S.C. inj. of 70 mg. See lit.
    Tmt. should be initiat. by physicians experienced in the diagnosis and tmt. of migraine.
    C/I: Hypersens.

    Repatha
    Amgen
    RX
    partial basket chart
    Repatha

    Human Monoclonal Antibody. Evolocumab 140 mg/ml.
    PRE-FILL.SYR.: 1, 2, 3, 6. Prim. hypercholesterolem & mixed dyslipidem. in adult.: either 140 mg every two wks. or 420 mg once month.; both doses are clinic. equiv.
    Homozyg. famil. hypercholesterolem. in adult. and adolesc. ≥ 12 yrs.: The init. recomm. dose is 420 mg once month. After 12 wks. of tmt., dose frequency can be up-titrated to 420 mg once every 2 wks. if a clinic. meaningful response is not achieved. Pts. on apheresis may initiate tmt. with 420 mg every two wks. to corresp. with their apheresis schedule.
    Establish. atherosclerotic cardiovasc. dis. in adult.: 140 mg every two wks. or 420 mg once month.; both dosesare clinic. equiv.
    Pts. with ren.impair.- pts with mild- moder. ren. impair.,- No dose adjust. is necessary in pts. with severe ren. impair. (eGFR<30 mL/min/1.73 m²).
    Pts. with hep. impair.- No dose adjust. is necessary in pts. with mild hep. impair. See lit.
    Hypercholesterolem. & and mixed dyslipidem., in adults with primary hypercholesterolem. (heterozygous famil. and non-famil.) or mixed dyslipidem., as an adjunct to diet: In comb. with a statin or statin with other lipid-lowering therap. in pts. unable to reach LDL-C goals with the max. tolerated dose of a statin or, alone or in comb. with other lipid-lower. therap. in pts. who are statin-intoler., or for whom a statin is contraindic.
    Homozygous famil. hypercholesterolem.–adult. & adolesc. ≥12 yrs. and over with homozyg. famil. hypercholesterolem. in comb. with other lipid-lower. therap.
    Establish. atherosclerotic cardiovasc. dis.-adults with established atherosclerotic cardiovasc. dis. (MI, stroke or peripher. arterial dis.) to reduce cardiovasc. risk by lower. LDL-C levels, as an adjunct to correct. of other risk factors: In comb. with the maxim. tolerated dose of a statin with/without other lipid-lower. therap.
    Alone or in comb. with other lipid-lower. therap. in pts. who are statin-intoler., or for whom a statin is contraindic.
    C/I: Hypersens.

    CLOSE